Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection

Next Previous
Trial Profile

Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amoxicillin (Primary) ; Esomeprazole (Primary) ; Rifabutin (Primary) ; Clarithromycin; Tinidazole
  • Indications Helicobacter pylori infections
  • Focus Therapeutic Use

Most Recent Events

  • 09 Mar 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (Last verified October 2020).
  • 09 Mar 2021 Planned End Date changed from 31 Jan 2023 to 31 Jul 2023.
  • 09 Mar 2021 Planned primary completion date changed from 31 Dec 2022 to 31 May 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top